Compare · CRON vs DFTX
CRON vs DFTX
Side-by-side comparison of Cronos Group Inc. (CRON) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRON and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.57B, about 2.5x CRON ($1.03B).
- Over the past year, CRON is up 40.9% and DFTX is up 203.4% - DFTX leads by 162.5 points.
- DFTX has hit the wire 3 times in the past 4 weeks while CRON has been quiet.
- CRON has more recent analyst coverage (11 ratings vs 4 for DFTX).
- Company
- Cronos Group Inc.
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.03B
- $2.57B
- 1M return
- +4.75%
- +0.68%
- 1Y return
- +40.92%
- +203.41%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 3
- Recent ratings
- 11
- 4
Cronos Group Inc.
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under two adult-use brands, COVE and Spinach. The company also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Latest CRON
- Officer Doucet Terrence Gregory Joseph converted options into 10,597 shares and covered exercise/tax liability with 5,199 shares, increasing direct ownership by 5% to 110,588 units (SEC Form 4)
- Officer Wagner Adam converted options into 10,367 shares, increasing direct ownership by 11% to 103,987 units (SEC Form 4)
- Officer Buggy Shannon converted options into 20,622 shares and covered exercise/tax liability with 9,179 shares, increasing direct ownership by 7% to 178,322 units (SEC Form 4)
- Officer Kenost Jared Matthew converted options into 9,412 shares and covered exercise/tax liability with 3,701 shares, increasing direct ownership by 15% to 42,974 units (SEC Form 4)
- Officer Weigensberg Arye converted options into 3,118 shares, increasing direct ownership by 1% to 211,555 units (SEC Form 4)
- Officer Wagner Adam converted options into 20,470 shares, increasing direct ownership by 28% to 93,620 units (SEC Form 4)
- Officer Kenost Jared Matthew covered exercise/tax liability with 4,774 shares and converted options into 12,649 shares, increasing direct ownership by 27% to 37,263 units (SEC Form 4)
- SEC Form 10-Q filed by Cronos Group Inc.
- Cronos Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Cronos Expands Pre-Roll Portfolio with Spinach STIX®
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026